The value of personalised medicines for healthcare systems in Europe

Bookmark and Share
Published: 10 Jul 2019
Views: 264
Anthony Barron - European Biopharmaceutical Enterprises (EBE) and the European Federation of Pharmaceutical Industries and Associations (EFPIA), Belgium

Anthony Barron speaks to ecancer at the WIN 2019 Symposium in Paris about the benefits of personalised treatments to patients, healthcare systems and society.

He explains the main benefits of this type of targeted treatment which include decreased hospitalisation costs, increased overall survival and reduced side effects.

Barron also mentions strategic and organisational barriers that still remain, including screening strategies and access to diagnostic technologies.

He also gives examples of some countries that have successfully implemented genomic strategies and national cancer plans. However, funding still remains to be the biggest hurdle in implementing an effective and accessible care strategy.